Announcements Trials
Browse Landscape

Status

Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Malnutrition 2Hyperphagia 1

Interventions

Cyclophosphamide 17blinatumomab 16fludarabine 13Vincristine 11Cytarabine 10tisagenlecleucel 8pegaspargase 8nilotinib 8Methotrexate 8Inotuzumab Ozogamicin 8Clofarabine 8venetoclax 7Dexamethasone 7asparaginase erwinia chrysanthemi recombinant 6Dasatinib 6Azacitidine 5AP 1903 reagent 5aflibercept 4Mercaptopurine 4Imatinib Mesylate 4Filgrastim 4Etoposide 4Drug Therapy 4Daunorubicin 4ponatinib 3Sensitivity and Specificity 3Mitoxantrone 3Immunotherapy, Adoptive 3Granulocyte Colony-Stimulating Factor 3CPX-351 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Precursor Cell Lymphoblastic Leukemia-Lymphoma × fish oil triglycerides × Clear all
NCT06274788 2025-09-05

Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment

Fresenius Kabi

Recruiting
40 enrolled
LymphoidOther hematologic neoplasm

Malnutrition, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04807478 2022-08-04

Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis (PNAC)

Fresenius Kabi

Withdrawn
LymphoidOther hematologic neoplasm

Malnutrition, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡